CClinicalTrials.gg
CompletedNCT02484586Updated Sep 11, 2017

Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses

An interventional study of Etafilcon A and Etafilcon A in Presbyopia and Refractive Error, sponsored by Brien Holden Vision. Completed at 1 site in Australia. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-11.

Sponsored by Brien Holden Vision · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to assess the visual performance of multiple optimised prototype soft contact lens designs compared to commercially available contact lenses.

Read the detailed description

Prospective, double-masked, crossover, bilateral wear, dispensing clinical trial where participants will wear multiple prototype (test) and commercial (control) lenses.

Multiple prototype contact lens designs will be assessed against commercial control lenses during the study, where each design will be worn for up to a week. There will be a minimum 1 night washout period between lens designs.

02

Conditions studied

  • Presbyopia
  • Refractive Error

Keywords

  • Presbyopia
  • Refractive error
  • Contact lens
03

In context

Presbyopia

324 studies on the registry are indexed under Presbyopia; 33 are open to participants now.

This study's enrollment of 161 is above the median of 61 across 265 interventional studies indexed under Presbyopia.

Browse Presbyopia studies →

Lead sponsor

Brien Holden Vision is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent.
  • Be at least 18 years old, male or female.
  • Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator.
  • Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses.
  • Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses.
  • Be suitable and willing to wear contact lenses.

Exclusion criteria

Exclusion Criteria:

  • Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses.
  • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants.
  • Use of or a need for concurrent category S3 and above ocular medication at enrolment. Ocular medication can be prescribed during the course of the trial as per standard optometric practice.
  • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial. Note: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
  • Eye surgery within 12 weeks immediately prior to enrolment for this trial.
  • Previous corneal refractive surgery.
  • Contraindications to contact lens wear.
  • Known allergy or intolerance to ingredients in any of the clinical trial products.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Other
    Presbyope group

    40 years and over with a reading add. Control lens: Etafilcon A, Nelfilcon A, Nesofilcon A, Somofilcon A, 58% Poly-HEMA Test lens: Etafilcon A Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by each participant for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit.

    Device: Etafilcon A · Device: Nelfilcon A · Device: Nesofilcon A · Device: Somofilcon A · Device: 58% Poly-HEMA

  • Other
    Non-Presbyope group

    18-39 years with no reading add. Control lens: Etafilcon A, Nelfilcon A, Omafilcon A Test lens: Etafilcon A Up to 10 prototype contact lens designs and at least 1 commercially available contact lens designs will be worn by participants for up to a week on a daily disposable modality. Participants will attend separate fitting and assessment visits for each lens type (Fitting Visit on Day 1, and Assessment Visit as late as Day 7, but may be as early as 6 hours after the Fitting Visit). There will be a minimum 1 night washout period between lens designs, i.e. after an assessment visit but before the next fitting visit.

    Device: Etafilcon A · Device: Nelfilcon A · Device: Omafilcon A

Interventions

  • DeviceEtafilcon A

    Prototype lens material

  • DeviceEtafilcon A

    Control lens for presbyope group

    Also known as: 1-Day Acuvue Moist Multifocal

  • DeviceNelfilcon A

    Control lens for presbyope group

    Also known as: Dailies Aqua Comfort Plus Multifocal

  • DeviceNesofilcon A

    Control lens for presbyope group

    Also known as: Biotrue ONEday for Presbyopia

  • DeviceNelfilcon A

    Control lens for non-presbyope group

    Also known as: Dailies Aqua Comfort Plus

  • DeviceEtafilcon A

    Control lens for non-presbyope group

    Also known as: 1-Day Acuvue Moist

  • DeviceSomofilcon A

    Control lens for presbyope group

    Also known as: Clariti 1 Day Multifocal

  • Device58% Poly-HEMA

    Control lens for presbyope group

    Also known as: SEED 1dayPure moisture Multistage

  • DeviceOmafilcon A

    Control lens for non-presbyope group

    Also known as: Proclear Multifocal

06

What researchers measure

Primary outcomes

  1. Visual acuity on a LogMAR (logarithm of the minimum angle of resolution) scale

    For each lens, visual acuity will be measured at distance with a computerised LogMAR chart and at near with a near LogMAR chart. Data will be summarised as means +/- standard deviations. No transformation is likely to be required. Visual acuity will be compared between each lens design and control lens types. The significance of lens design will be determined for each visit. Repeated effects linear mixed model with subject random intercepts or paired t tests will be employed for the analysis of visual acuity. Analysis will be performed within each study arm namely presbyopes and non-presbyopes.

    Time frame: Approximately 1 week after lens fitting

Secondary outcomes

  1. Subjective rating of vision on a 1-10 visual analogue scale

    For each lens, subjective ratings of vision will be assessed with a questionnaire based on a 1 to 10 scale in steps of 1. The questionnaire has been designed specifically for this study. Data will be summarised as means +/- standard deviations. No transformation is likely to be required. Subjective ratings will be compared between each lens design and control lens types. The significance of lens design will be determined for each visit. Repeated effects linear mixed model with subject random intercepts or paired t tests will be employed for the analysis of subjective ratings. Analysis will be performed within each study arm namely presbyopes and non-presbyopes.

    Time frame: Approximately 1 week after lens fitting

07

Study locations

1 site
  • Brien Holden Vision Institute
    Sydney, New South Wales 2052, Australia
08

References and documents

Publications

  • Jong M, Tilia D, Sha J, Diec J, Thomas V, Bakaraju RC. The Relationship between Visual Acuity, Subjective Vision, and Willingness to Purchase Simultaneous-image Contact Lenses. Optom Vis Sci. 2019 Apr;96(4):283-290. doi: 10.1097/OPX.0000000000001359. PubMed 30907859 ↗
  • Sha J, Tilia D, Kho D, Amrizal H, Diec J, Yeotikar N, Jong M, Thomas V, Bakaraju RC. Visual Performance of Daily-disposable Multifocal Soft Contact Lenses: A Randomized, Double-blind Clinical Trial. Optom Vis Sci. 2018 Dec;95(12):1096-1104. doi: 10.1097/OPX.0000000000001311. PubMed 30451806 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02484586
Lead sponsor
Brien Holden Vision
Responsible party
Sponsor
First posted
Jun 29, 2015
Start date
Oct 2015
Primary completion
Feb 7, 2017
Completion
Feb 7, 2017
Last update
Sep 11, 2017

Study contacts

Jennifer Sha, BOptom/BSc
principal investigator · Brien Holden Vision Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion